- www.prnewswire.com reports: The 2026 Tang Prize in Biopharmaceutical Science has been awarded to Drs. Steven A. Rosenberg, Michel Sadelain, and Carl H. June, as reported by PR Newswire. This prestigious award recognizes their groundbreaking contributions to cellular immunotherapy.
- Their pioneering work includes the discovery and development of tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR-T) therapies. These innovations have profoundly impacted cancer treatment.
- According to PR Newswire, these advanced therapies have revolutionized the approach to fighting cancer. They offer new hope for patients suffering from both blood cancers and solid tumors.
- The recognition underscores the significant advancements made in harnessing the body's own immune system to combat cancer effectively. This represents a major breakthrough in medical science.
- Drs. Rosenberg, Sadelain, and June's efforts are celebrated for their potential to transform patient outcomes. PR Newswire highlights their role in "revolutioniz[ing] cancer treatment."
2026 Tang Prize for Immunotherapy Pioneers
Drs. Steven A. Rosenberg, Michel Sadelain, and Carl H. June have been awarded the 2026 Tang Prize in Biopharmaceutical Science for their groundbreaking contributions to cellular immunotherapy. Their pioneering development of tumor-infiltrating lymphocyte (TIL) and CAR-T therapies has revolutionized cancer treatment, offering new hope for patients with both blood cancers and solid tumors.
Reporting Sources
1
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
